Global first for Salford team in rare disease study

Press/Media: Research

Release date: 4/12/2019

Description

Congratulations to the Salford Royal Core Research Team, Professor Hector Chinoy (PI) and Dr James Lilleker for dosing the first patient globally in a study testing the efficacy and safety of a new treatment for a rare inflammatory muscle disease.

Media coverage

TitleFirst global patient takes part in trial of new drug to treat rare inflammatory muscle disease
Degree of recognitionInternational
Media name/outletManchester NIHR BRC
Media typeWeb
CountryUnited Kingdom
Date9/01/20
URLhttps://www.manchesterbrc.nihr.ac.uk/news-and-events/first-global-patient-takes-part-trial-new-drug-treat-rare-inflammatory-muscle-disease/
PersonsJames Lilleker
TitleGlobal first for Salford team in rare disease study
Degree of recognitionInternational
Media name/outletNorthern Care Alliance Research and Innovation
Media typeWeb
CountryUnited Kingdom
Date9/12/19
DescriptionCongratulations to the Salford Royal Core Research Team, Professor Hector Chinoy (PI) and Dr James Lilleker for dosing the first patient globally in a study testing the efficacy and safety of a new treatment for a rare inflammatory muscle disease.
Producer/AuthorNCA
URLhttps://www.ncaresearch.org.uk/news/global-first-for-salford-team-in-rare-disease-study/
PersonsJames Lilleker, Hector Chinoy
TitleRa Pharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of Zilucoplan for IMNM
Degree of recognitionInternational
Media name/outletRaPharma and Business Wire
Media typeWeb
CountryUnited Kingdom
Date4/12/19
DescriptionCAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 4, 2019-- Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the initiation of dosing in its Phase 2 clinical trial of zilucoplan for the treatment of immune-mediated necrotizing myopathy (IMNM).
URLhttps://rapharma.gcs-web.com/news-releases/news-release-details/ra-pharmaceuticals-announces-dosing-first-patient-phase-2
PersonsJames Lilleker, Hector Chinoy

Related information